Aspergillosis is a group of diseases that occur from aspergillus infection. Aspergillus is a fungus whose spores are present in the air, but does not normally cause illness. Individuals with damaged lungs, sensitive immune system, and allergies are more prone to Aspergillus induced infection. Common Aspergillus infections include invasive Aspergillosis, non-invasive Allergic Pulmonary Aspergillosis (ABPA), and Chronic Pulmonary and Aspergilloma (CPA). Invasive aspergillosis is uncommon and occurs primarily in immunocompromised people. Chronic pulmonary aspergillosis is rare pulmonary disease, which increases symptoms of respiratory disorders such as asthma. According to a study published by European Respiratory Society (ERS) publications, in 2015, CPA is estimated to affect nearly 240,000 people in Europe. The most common form of CPA is Chronic Cavitary Pulmonary Aspergillosis (CCPA), which if left untreated can develop chronic fibrosing pulmonary aspergillosis. According to a statistics published by Centers for Disease Control and prevention, (CDC) an estimated 10% of individuals with asthma or cystic fibrosis experience an allergic reaction to aspergillus. ABPA is estimated to affect 2-15% of patients with cystic fibrosis and around 2% of all asthma patients.
Aspergillosis Treatment Market Dynamics
Increasing prevalence of Aspergillosis and favorable government regulations are the major factors driving growth of the Aspergillosis treatment market. According to a study published in Journal of Fungi 2016, CPA is estimated to affect nearly three million people globally making it major health problem resulting in mortality and morbidity. Aspergillosis infection can be treated with antifungal and corticosteroids drugs. Corticosteroid drugs are prescribed for allergic bronchopulmonary aspergillosis treatment. These drugs reduce inflammation and lowers respiratory symptoms such as coughing and wheezing. Some of the most frequently used drugs are methylprednisolone, prednisolone and prednisone. The U.S. Food & Drug Administration (FDA) approved various drugs for Aspergillosis infection treatment. For instance, in 2015, the U.S. FDA approved Isavuconazonium (Astellas Pharma), a prodrug form of Isavuconazole. Antifungal drugs are majorly used to treat invasive pulmonary Aspergillosis. Voriconazole, an antifungal drug is widely used due to less side effects and more effectiveness in comparison to other drugs. Itraconazole or Amphotericin B also treat the infection effectively. Caspofungin is used to treat infection, resistant to the other antifungals. Furthermore, antifungal drugs are sometimes used in combination with corticosteroids for treating ABPA. Surgeries may be required in some cases where aspergillomas are present leading to serious problems such as excessive bleeding. Antifungal drugs are generally not effective against aspergillomas, therefore surgery such as embolization is recommended. An aspergilloma is a solid mass of Aspergillus hyphae, mucus, fibrin, and other cellular debris, formed inside a pre-existing area of pulmonary cavity or scar. Patent expiration of branded products and drug resistance to antifungal medications are the factors restraining growth of the market. Moreover, antifungals can also cause serious side effects such as liver and kidney damage.
Aspergillosis Treatment Market Regional Insights
Regional segmentation of Aspergillosis treatment market by Coherent Market Insights, includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America Aspergillosis treatment market is expected to hold a dominant position, due to increasing government initiatives for diagnosing and treatment of infection. In 2016, the Infectious Diseases Society of America (IDSA) published new guidelines for the diagnosis and treatment of infections due to Aspergillus species. The document offers guidance on non-culture-based identification of Aspergillus infections and dejects the use of combination anti-fungal therapy for primary management. The guidelines also define therapy of isavuconazole, a new U.S. FDA approved anti-fungal drug in March 2015 to treat mucormycosis and aspergillosis. Asia pacific Aspergillosis treatment market share is expected to witness significant growth during the forecast period, owing to large volume of untreated patients. Many countries in the region lack resources for suitable infection diagnostics and control. Opportunistic invasive fungal infections (IFIs) have a substantial impact on public health in the region, which requires early diagnosis and suitable treatment. The occurrence of IFI in the Asia Pacific region is increasing due to increased population of immunosuppressed patients resulting from transplantation and treatments for cancer, as well as the impact of HIV.
Aspergillosis Treatment Market Competitive Analysis
Major players operating in the aspergillosis treatment market include Abbott laboratories, AstraZeneca plc, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson Services, Inc., Mylan Pharmaceuticals, Inc., Novartis AG, Pfizer, Inc., and Takeda Pharmaceutical Company Ltd.
Aspergillosis Treatment Market Taxonomy
On the basis of drugs class, the aspergillosis treatment market is segmented into:
On the basis of disease type, the aspergillosis treatment market is segmented into:
- Invasive Aspergillosis
- Chronic Pulmonary Aspergillosis
- Allergic Bronchopulmonary Aspergillosis
- Allergic Aspergillus Sinusitis
- Cutaneous Aspergillosis